Stockscreener 앱 받기
29.30
1.12%
-0.215
전일 마감가:
$29.52
열려 있는:
$29.22
하루 거래량:
42,801
Relative Volume:
0.10
시가총액:
$1.29B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.24%
1개월 성능:
+23.32%
6개월 성능:
+196.04%
1년 성능:
+0.00%
1일 변동 폭
$28.98
$30.26
1주일 범위
$27.54
$31.93
52주 변동 폭
$6.71
$31.93
Maze Therapeutics Inc Stock (MAZE) Company Profile
명칭
Maze Therapeutics Inc
전화
(650) 850-5070
주소
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
MAZE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
29.36 | 1.43B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.38 | 107.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.40 | 64.39B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.92 | 61.13B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
828.09 | 52.30B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
314.25 | 34.99B | 4.56B | -176.77M | 225.30M | -1.7177 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-02 | 개시 | BTIG Research | Buy |
| 2025-07-23 | 개시 | H.C. Wainwright | Buy |
| 2025-07-08 | 개시 | Wedbush | Outperform |
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Maze Therapeutics Inc. recovery potential after sell offPortfolio Risk Summary & Fast Entry Momentum Alerts - newser.com
Pattern recognition hints at Maze Therapeutics Inc. upsideWeekly Trade Review & Long-Term Safe Investment Plans - newser.com
Does Maze Therapeutics Inc. qualify in momentum factor screeningNew Guidance & Verified Momentum Stock Watchlist - newser.com
Developing predictive dashboards with Maze Therapeutics Inc. dataJuly 2025 Opening Moves & Advanced Technical Signal Analysis - newser.com
Will Maze Therapeutics Inc. outperform the marketPortfolio Update Report & Verified Momentum Watchlists - newser.com
What is the fair value of Maze Therapeutics Inc. stock nowJuly 2025 Levels & Precise Buy Zone Identification - newser.com
Can Maze Therapeutics Inc. stock beat market expectations this quarterPortfolio Profit Report & Real-Time Buy Zone Alerts - newser.com
Why Maze Therapeutics Inc. is moving todayWeekly Profit Recap & Verified High Yield Trade Plans - newser.com
Can Maze Therapeutics Inc. stock deliver sustainable ROEJuly 2025 Action & Real-Time Stock Price Movement Reports - nchmf.gov.vn
Is Maze Therapeutics Inc. stock a top momentum playTrade Exit Summary & Community Consensus Stock Picks - nchmf.gov.vn
Will Maze Therapeutics Inc. stock rally after Fed decisionsQuarterly Market Review & Technical Entry and Exit Alerts - nchmf.gov.vn
What drives Maze Therapeutics Inc stock priceDividend Growth Stocks & Analyze Your Portfolio Risk in Seconds - earlytimes.in
Portfolio Update: Will Maze Therapeutics Inc. stock benefit from AI adoptionMarket Volume Report & Verified Momentum Watchlists - nchmf.gov.vn
Will Maze Therapeutics Inc. stock benefit from AI adoptionPortfolio Return Summary & Verified Chart Pattern Signals - nchmf.gov.vn
ETFs Investing in Maze Therapeutics, Inc. Stocks - TradingView
Weiss Ratings Reaffirms "Sell (D)" Rating for Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Can a trend reversal in Maze Therapeutics Inc. lead to recovery2025 Fundamental Recap & Capital Protection Trade Alerts - newser.com
How to use a screener to detect Maze Therapeutics Inc. breakoutsWall Street Watch & Free Daily Entry Point Trade Alerts - newser.com
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Forecast to 2035 Featuring Amicus Therapeutics, Astellas, BioMarin, Maze Therapeutics, Oxyrane ParasailResearchAndMarkets.com - The AI Journal
Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year HighWhat's Next? - MarketBeat
Maze Therapeutics Appoints Herve Hoppenot as Board Chairman - MarketScreener
What technical models suggest about Maze Therapeutics Inc.’s comeback2025 Major Catalysts & Long Hold Capital Preservation Plans - newser.com
Maze Therapeutics appoints Hervé Hoppenot as chairman of the board - Investing.com
Maze Therapeutics Appoints Hervé Hoppenot as Chairman - TipRanks
Maze Therapeutics appoints Hervé Hoppenot as board chairman - Investing.com India
Maze Therapeutics appoints Hervé Hoppenot as board chairman By Investing.com - Investing.com Australia
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors - GlobeNewswire
Detecting price anomalies in Maze Therapeutics Inc. with AI2025 Sector Review & Growth Focused Stock Pick Reports - newser.com
Predicting Maze Therapeutics Inc. trend using moving averages2025 Top Decliners & Verified Swing Trading Watchlist - newser.com
Maze Therapeutics (MAZE): Assessing Current Valuation Following a 78% Monthly Share Price Surge - Sahm
Maze Therapeutics (MAZE): Assessing Valuation After 78% 30-Day Share Price Surge - Yahoo Finance
Maze Therapeutics Inc (MAZE) 재무 분석
Maze Therapeutics Inc (MAZE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.05%
0.40%
자본화:
|
볼륨(24시간):